*ST双成：2025年全年净利润预计同比扭亏

Core Viewpoint - *ST Shuangcheng is expected to turn a profit in 2025, with a projected net profit attributable to shareholders ranging from 16 million to 23 million yuan, marking a significant turnaround from previous losses [1] Financial Performance - The company anticipates a total profit growth of 107.53% to 111.30% year-on-year for the reporting period [1] - The net profit attributable to shareholders is expected to increase by 120.43% to 129.37% year-on-year [1] - The net profit excluding non-recurring gains and losses is projected to be between 14 million and 20 million yuan, also indicating a turnaround from losses [1] Factors Influencing Profit Changes - The company is focusing on international development to counteract domestic drug price declines, leading to steady growth in export sales and successful overseas project registrations [1] - The approval of the U.S. registration application for injectable paclitaxel (albumin-bound) is expected to drive significant revenue growth [1] - The absence of fair value loss from financial products in the current reporting period, which was present in the previous year, has positively impacted profit [1] - A reduction in asset impairment losses during the reporting period has also contributed to the overall improvement in operational performance [1]